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Summary
Inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1 and cIAP2 are upregulated in many
cancer cells. It has been thought that small molecule mimetics of Smac, an endogenous IAP
antagonist, might potentiate apoptosis in cancer cells by promoting caspase activation. However,
three recent papers in Cell (Vince et al., 2007; Varfolomeev et al., 2007) and Cancer Cell
(Petersen et al., 2007) now report that Smac mimetics primarily kill cancer cells via a different
mechanism, the induction of autoubiquitination and degradation of cIAPs, which culminates in
TNFα-mediated cell death. These studies may accelerate the introduction of Smac mimetics in
cancer therapy.
Re-establishing the apoptotic program is a much dreamed about strategy for cancer therapy.
One possible approach involves small molecules that mimic the antagonistic activity of
Smac (also known as Diablo) towards inhibitor of apoptosis (IAP) proteins. Smac and its
synthetic small molecule mimetics interact with the BIR domains in IAPs such as XIAP,
cIAP1, and cIAP2. Because XIAP is a bona fide caspase inhibitor, it was presumed that
Smac mimetics primarily target XIAP and therefore allow caspase-9 activation to occur to
trigger apoptosis. In contrast to XIAP, cIAP1 and cIAP2 are weak caspase inhibitors in
vitro, but associate with two tumor necrosis factor receptor (TNFR) signaling proteins
TRAF1 and TRAF2 to participate in TNFα-induced NF-κB activation (Rothe et al., 1995). It
has been hoped that Smac mimetics could be used in combination with chemo- or radiation
therapy that activates caspase-9 via the mitochondrial apoptotic pathway. In principal, this
combination therapy should enhance cancer cell apoptosis by relieving any caspase activities
held in check by IAPs.
In three related papers by Vucic, Wang, Silke and their colleagues, Smac mimetics exceed
expectations as potentiators of cancer cell apoptosis by exhibiting the ability to induce cell
death in multiple cancer cell lines even when used alone (Petersen et al., 2007; Varfolomeev
et al., 2007; Vince et al., 2007). The three groups independently developed small molecules
that mimic the N-terminal AVPI sequence of mature Smac but are different in their detailed
chemical structures. All but one of the developed Smac mimetics are dimeric, resembling
the dimeric structure of Smac. As evidence that this killing activity is likely not due to off-
target toxicity, the Smac mimetic used by Petersen et al. (2007) only pulled down its
intended targets XIAP, cIAP1, and cIAP2, and their associated proteins TRAF1 and TRAF2.
Surprisingly, cell death induced by the Smac mimetics is dependent on caspase-8, but not
caspase-9 (Petersen et al., 2007; Varfolomeev et al., 2007) and this cell death can be
prevented by the caspase-8 inhibitor crmA (Vince et al., 2007). Because caspase-8 is the
primary initiator caspase in the apoptotic pathway mediated by death receptors (such as Fas,
TRAIL receptors, and TNF receptor 1) the dependence on caspase-8 is consistent with the
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earlier observed synergy between Smac mimetics and death receptor ligands (Li et al.,
2004). However, the molecular mechanism by which Smac mimetics induced caspase-8
dependent apoptosis remained completely unknown.
Elegant independent studies by the three groups have now uncovered TNFα, a death
receptor ligand, as the major culprit in cancer cell apoptosis induced by Smac mimetics
(Petersen et al., 2007; Varfolomeev et al., 2007; Vince et al., 2007). siRNA knockdown of
TNF receptor 1 (TNFR1) but not of Fas, TRAIL-R1 and TRAIL-R2 prevented Smac
mimetic-induced apoptosis of cancer cell. Similarly, specific knockdown of TNFα but not
FasL or TRAIL promoted the survival of cells treated with Smac mimetics (Petersen et al.,
2007; Varfolomeev et al., 2007).. Thus, the emerging model (Figure 1) is that in addition to
targeting XIAP to relieve caspase-9 inhibition in the intrinsic cell death pathway, Smac
mimetics target cIAPs, especially cIAP1, to stimulate their auto-ubiquitination and
degradation, leading to NF-κB activation and TNFα secretion. The autocrine TNFα
signaling in turn induces caspase-8 activation and cancer cell death.
The first dramatic effect of Smac mimetics is the induction of cIAP1 and cIAP2 degradation
within minutes of treatment without affecting the levels of other IAPs or TRAFs
(Varfolomeev et al., 2007; Vince et al., 2007). The degradation of cIAP1 and cIAP2 is
dependent on the concentration of the Smac mimetic, with cIAP1 degradation occurring at a
much lower concentration than cIAP2. Because cIAPs are ubiquitin ligases capable of auto-
ubiquitination and ubiquitination of several binding proteins, it was suspected that their
degradation might depend on the proteasome. Indeed, the proteasome inhibitor MG132
prevented the loss of cIAP1 and cIAP2 induced by the Smac mimetic (Varfolomeev et al.,
2007; Vince et al., 2007). In contrast, the pan-caspase inhibitor z-VAD did not have any
effect on cIAP1 and cIAP2 degradation. For Smac mimetic-induced degradation to occur,
the IAP proteins require both a functional RING domain and an intact interaction site for a
Smac mimetic. Furthermore, in vitro reconstitution of the auto-ubiquitination reaction using
purified E1, E2 (UbcH5a) and cIAP1 showed that Smac mimetics quickly and markedly
enhanced auto-ubiquitination of cIAP1 (Varfolomeev et al., 2007).
How Smac mimetics stimulate cIAP1 auto-ubiquitination remains unclear. Although a
bivalent Smac mimetic induces dimerization of the cIAP1 BIR2-BIR3 domain in vitro, this
dimerization is not a prerequisite for cIAP1 ubiquitination and degradation, as the
monovalent Smac mimetic is equally effective at similar concentrations (Varfolomeev et al.,
2007). Another possibility is offered by the fact that many ubiquitin ligases stimulate their
own ubiquitination in the absence of their substrates. However, the Smac mimetics did not
dissociate cIAPs from TRAF2, and hence cIAPs likely stay bound with TRAF2-associated
ubiquitination targets (Varfolomeev et al., 2007). At the moment, the most plausible
explanation is that Smac mimetics alter the protein conformation of cIAPs to allow better
access of the Lys residues to the E2s bound to the RING domain.
Loss of cIAPs induces activation of both the canonical and non-canonical NF-κB signaling
pathways as manifested by IκB degradation and p100 processing, respectively. Remarkably,
IκB phosphorylation occurs within minutes of treatment of Smac mimetics, with kinetics
that are similar to TNFα-induced NF-κB activation. IκB phosphorylation and degradation is
not affected by co-treatment with an inhibitor of TNFR1 signaling, demonstrating that
receptor signaling is not involved in activation of the canonical NF-κB pathway by the Smac
mimetic (Varfolomeev et al., 2007). An increase in the recruitment of the kinase RIP1
(receptorinteracting protein 1) to the TNFR1 signaling complex was observed after short
treatment of a Smac mimetic (Vince et al., 2007). Increased RIP1 recruitment was also
observed in cIAP1-deficient mouse embryonic fibroblasts (MEFs), which cannot be further
increased by Smac mimetic treatment (Vince et al., 2007), suggesting that loss of cIAP1 is
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responsible for the increased recruitment of the RIP1. Because RIP1 binding to TNFR1 is
known to result in NF-κB activation, it is argued that loss of cIAP1 leads to activation of the
canonical NF-κB pathway via increased RIP1 recruitment to TNFR1 (Vince et al., 2007).
However, because the pull down establishing enhanced RIP1 recruitment was performed
with Fc-TNFα and not with an antagonistic antibody to TNFR1, the possibility exists that
the increased RIP1 recruitment is dependent on TNFα, rather than a direct effect of the Smac
mimetics.
The mechanism for the activation of the non-canonical NF-κB pathway by Smac mimetics is
more clearly elucidated (Varfolomeev et al., 2007; Vince et al., 2007). A highly labile kinase
NIK is a crucial player in this pathway. It phosphorylates IKKα, leading to p100
phosphorylation and processing to p52. NIK constitutively associates with TRAFs, such as
TRAF2 and TRAF3, which have been shown to negatively regulate the non-canonical NF-
κB pathway (He et al., 2007; Malinin et al., 1997). Because TRAF2 in turn forms a
constitutive complex with cIAPs, it was hypothesized that cIAPs may be the ubiquitin ligase
for NIK ubiquitination and responsible for the instability of NIK in cells. Indeed, co-
expression of NIK with cIAP1 or cIAP2 led to disappearance of NIK whereas co-expression
with a RING domain mutant of cIAP1 did not. Treatment of cells stably expressing NIK
with a Smac mimetic triggered degradation of endogenous cIAP1 and a remarkable increase
of the NIK protein level. The Smac mimetic-induced processing of p100 occurs with much
slower kinetics than IκB phosphorylation, presumably due to the time required to synthesize
and to accumulate NIK to a functional level. Degradation of cIAP1 and stabilization of NIK
are also components of the physiological non-canonical NF-κB pathway as shown by
treatment with the TNF-like ligand TWEAK (Varfolomeev et al., 2007).
Activation of the NF-κB signaling pathway leads to the induction of many genes. An
important effector protein in this case is TNFα, which is only induced in cancer cell lines
sensitive to treatment with Smac mimetics (Varfolomeev et al., 2007; Vince et al., 2007).
What determines whether NF-κB activation induces TNFα production is not known.
Sensitive cell lines already secrete TNFα before any treatment (Petersen et al., 2007),
although it is unknown whether TNFα secretion is further increased in these same cell lines
upon treatment with Smac mimetics. It is also unclear whether only one or both of the
canonical and non-canonical NF-κB pathways is required for TNFα induction. A more in-
depth analysis will be required to clarify this point.
Remarkably, loss of cIAPs due to Smac mimetic treatment also appears to assist TNFα-
induced cell death. Unlike FasL, TNFα does not readily induce cell death in most
circumstances. Rather, it activates NF-κB and MAP kinases, leading to cell survival and cell
activation. Previous studies have shown that TNFα-induced cell death is accomplished via a
secondary TRADD-RIP1-FADD-caspase-8 complex devoid of TNFR1 (Micheau and
Tschopp, 2003). In keeping with this notion, RIP1 is also required for cell death induced by
a Smac mimetic, even in the presence of exogenous TNFα for both sensitive cancer cell
lines and those that are resistant to Smac mimetics alone but do respond to co-stimulation by
TNFα (Petersen et al., 2007). In contrast, knockdown of the adaptor protein TRADD
somewhat increases apoptosis (Petersen et al., 2007). Immunoprecipitation of caspase-8
after Smac mimetic treatment revealed the formation of a RIP1-FADD-caspase-8 complex
that did not contain TRADD or TRAF2 (Petersen et al., 2007). The lack of TRADD and
TRAF2 in the death signaling complex is interesting as it is different from the classical view
in which TRADD serves as the central platform molecule for the recruitment of both
TRAF2 and FADD.
Is it possible that cancer cells respond to TNFα differently? In fact, a recent report also
showed that RIP1 is crucial in TNFα-induced cell apoptosis in human tumor cells (Jin and
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El-Deiry, 2006). RIP1 was first cloned as a Fas interacting protein that induces apoptosis
upon overexpression (Stanger et al., 1995) and was also shown to be essential for FasL-
mediated necrotic cell death (Holler et al., 2000). However, RIP1 knockout cells are
defective in TNFα-induced NF-κB activation (Kelliher et al., 1998). The apparent
involvement of RIP1 in both apoptosis and activation of NF-κB induced is consistent with
RIP1 as both a protein required for survival and a protein that can induce cell death when
overexpressed.
The studies collectively reveal that there may be three different kinds of cancer cells defined
by their resistance and sensitivity to Smac mimetics. The first type would be those that are
sensitive to Smac mimetics as single agents. In this type of cell, Smac mimetics induce or
perhaps enhance TNFα synthesis and secretion and render the cells sensitive to TNFα-
induced apoptosis by forming a RIP1-dependent caspase-8 activating complex. The second
type of cancer cells would be those that do not respond to Smac mimetic treatment alone,
but are sensitive to Smac mimetics when co-stimulated by exogenous TNFα. In these cells,
treatment with a Smac mimetic fails to induce TNFα secretion, but sensitizes the cells to
apoptosis induced by several death receptors. The precise mechanism for this pro-death
activity is not known. In fact, the increase in NF-κB activity seen in cells treated with Smac
mimetics would suggest that the contrary is more prevalent. However, it is likely that apart
from NF-κB, other signaling pathways such as JNK are activated to lead to the degradation
of the anti-apoptotic protein cFLIP (Chang et al., 2006). Third, there may be a type of cancer
cells that are resistant to co-treatment with Smac mimetics and TNFα. These cells do not
form a RIP1-dependent caspase-8 activating complex upon the co-treatment. It is interesting
that Smac mimetics induced degradation of cIAPs in all cell lines tested (Varfolomeev et al.,
2007), suggesting that additional switch points control the sensitivity to Smac mimetics.
In summary, the role of Smac mimetics in cancer cells appears to be two-fold (Figure 1).
First, they stimulate auto-ubiquitination of cIAPs, resulting in their proteasomal degradation.
This in turn leads to NIK stabilization and facilitates RIP1 recruitment. This results in the
activation of the non-canonical and canonical NF-κB pathways, causing TNFα production in
a substantial number of tumor cells. Second, Smac mimetics lead to sensitivity to TNFα-
induced cell death, likely through the degradation of cIAPs and by favoring the formation of
a RIP1-dependent caspase-8 activating complex. Further boosting the potential of Smac
mimetics for clinical use, Petersen et al., (2007) showed that cancer cells that are sensitive to
Smac mimetic treatment in vitro are also responsive to the same treatment in an in vivo
mouse model.
One might argue, however, that cIAPs are also present in non-transformed cells and that
Smac mimetics will be potentially toxic considering the rapid degradation of cIAP1 and
activation of NF-κB in primary MEFs upon Smac mimetic treatment (Vince et al., 2007).
Yet, Smac mimetics do not kill non-transformed cells even though increased RIP1
recruitment is observed. Moreover, cIAP1 knockout mice appear normal with respect to
TNFα-mediated NF-κB activation and cell death indicating a high selectivity for tumor cells.
It has been known for many years that cell transformation shifts the balance in death
receptor signaling pathways from pro-survival to pro-cell death. For example, TRAIL and
FasL preferentially kill transformed cells and spare most primary cells. Although the
molecular reason for this difference in sensitivity is still poorly understood, this absence of
knowledge does not impede the clinical trials that are ongoing with both of the TNF ligand
family members.
Ironically, TNFα was the first member of this family to be considered as an antitumor drug.
However, despite incredible expectations, the use of TNFα in the treatment of cancer
patients turned out to be limited to limb perfusion due to TNFα’s toxic proinflammatory
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activity when administered systemically. This may be set to change with the arrival of Smac
mimetics that trigger an increase in TNFα production at a barely detectable and non-toxic
level. The late William Coley, who first used stimulation of TNFα production by bacterial
infection to induce tumor regression in vivo in the late 1800s (Coley, 1893), would have
been very pleased.
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Figure 1. Cancer cell death induced by Smac mimetics
In non-stimulated cells, cIAPs bound to TRAF2 ubiquitinate and degrade the kinase NIK
thereby inhibiting the non-canonical NF-κB pathway. The addition of Smac mimetics
stimulates auto-ubiquitination of cIAPs, resulting in their proteasomal degradation, which in
turn leads to the stabilization of NIK. Moreover, TRAF2 “freed” from cIAPs facilitates
recruitment of the kinase RIP1 to tumor necrosis factor receptor 1 (TNFR1). This results in
the activation of the non-canonical and canonical NF-κB pathways, causing TNFα
production in a substantial number of tumor cells. Smac mimetics also lead to sensitivity to
TNFα-induced cell death, likely through the degradation of cIAPs, which are inhibitors of
apoptosis, and by favoring the formation of a RIP1-dependent caspase-8 activating complex.
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